Cooperative Agreement U01CA301480
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $4,236,812 Project Grant under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393) to Children's Hospital Los Angeles (CHLA). The grant, effective September 10, 2025 through August 31, 2029, will fund a study to evaluate the use of a patient navigation intervention to improve transition outcomes for young adult survivors of childhood cancer, particularly those from low socioeconomic status and underinsured/uninsured...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.393 - Cancer Cause and Prevention Research to St. Jude Children's Research Hospital Inc. for the "Evaluation of Cardiovascular Health Outcomes among Survivors 2 (ECHOS-2)" study. The $772,418 grant, awarded on September 1, 2025, will test the efficacy of an eHealth-delivered intervention to improve adherence to cardiomyopathy screening among adult survivors of childhood cancer. The study aims to enroll 350...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- This federal Project Grant award of $3,032,826 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports the "Fusion Oncoprotein Condensates in Pediatric Cancers" research program at St. Jude Children's Research Hospital. The program assembles leading scientists to collaboratively study fusion oncoproteins (FOs) that commonly drive pediatric cancers, including acute lymphoblastic/myeloid leukemias, ependymoma, and mesenchymal chondrosarcoma. The...
- The U.S. National Cancer Institute (NCI) awarded a $1,049,120 Project Grant to St. Jude Children's Research Hospital Inc. through the Cancer Biology Research federal grant program (CFDA 93.396). The project aims to "Dissect Neomorphic Functions Mediated by Mutant-Specific Structures of SPOP", with the goal of understanding how cancer-related mutations in the SPOP protein affect its structure and function to drive tumor development. The research will leverage the awardee's recent...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 - Cancer Treatment Research to St. Jude Children's Research Hospital Inc. for $768,713 on August 1, 2025. The funding supports research to dissect how the EP300 and CBP histone acetyltransferase proteins control cell state-specific phenotypes and chemosensitivity in high-risk neuroblastoma. The objectives are to capitalize on transcriptional control to identify mechanism-based, targeted cancer therapies that can...
- This $2,494,110 Cooperative Agreement was awarded on September 23, 2025 by the National Cancer Institute (NCI), under the federal Cancer Centers Support Grants program (CFDA 93.397). The grant aims to reduce ethnic disparities in outcomes for Latino children and adolescents with acute lymphoblastic leukemia (ALL) by identifying biological and social determinants of health factors contributing to adverse treatment-related toxicities and poor survival. The 5-year project will be administered by...
- This federal Project Grant award for $1,679,104 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by St. Jude Children's Research Hospital Inc. to investigate pre-mRNA splicing as a potential therapeutic vulnerability for pediatric liver cancer. The award, with a performance period from September 30, 2025 to September 29, 2028, will fund sophisticated scientific research, including the development of novel...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,295,000.00 to St. Jude Children's Research Hospital Inc. to conduct research aimed at creating cures for patients with Langerhans cell histiocytosis. The award period runs from September 1, 2024 to August 31, 2028. This research project builds upon St. Jude's extensive experience in pediatric cancer and other life-threatening diseases in...
- This federal Project Grant award in the amount of $767,328.00 was provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to St. Jude Children's Research Hospital Inc. to support research aimed at developing a novel therapeutic approach for treating neuroblastoma, a deadly childhood cancer. The key focus of this 5-year project is to investigate the efficacy of combining chemotherapy and immunotherapy with the drug indisulam, which selectively degrades the splicing...